December 22, 2016 / 5:44 AM / 9 months ago

Swiss stocks - Factors to watch on Dec 22

ZURICH, Dec 22 (Reuters) - The following are some of the main factors expected to affect Swiss stocks on Thursday:

ACTELION

The takeover battle surrounding Actelion heated up on Wednesday when the Swiss biotech company said it had begun exclusive talks with former suitor Johnson & Johnson about a “strategic transaction.”

For more click on

ROCHE

* The Swiss drugmaker announced positive results from three phase III studies for its investigational medicine Ocrevus against multiple sclerosis.

* It also announced its emicizumab for haemophilia A met the primary endpoint in a phase III study.

For more, click on

NOVARTIS

Sun Pharma said it was buying Novartis’ cancer drug Odomzo for global markets.

For more, click on

COMPANY STATEMENTS

* Credit Suisse plans to cut about 900 jobs in Switzerland next year, Bloomberg reported on Wednesday.

* Emmi AG said it acquired an 80 percent stake in Spanish goat’s milk processor Lacteos Caprinos S.A., but did not disclose the purchase price.

* Hochdorf Holding said it appointed Frank Hoogland as managing director Baby Care.

* Pax Anlage AG said it expected full-year net profit to exceed the previous year’s level.

* Perrot Duval said it generated a profit of 0.3 million Swiss francs in the six months to Oct. 31.

ECONOMY

Reporting by Zurich newsroom

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below